(R)-ND-336 

(R)-ND-336 is a potent and selective MMP-9 inhibitor with a K_i of 19 nM. (R)-ND-336 inhibits MMP-2 (K_i=127 nM) and MMP-14 (K_i=119 nM). (R)-ND-336 has the potential for diabetic foot ulcers (DFUs) research^[1].

(R)-ND-336 poorly inhibits other MMPs (K_i>100 μM). (R)-ND-336 has a long residence time (the time the inhibitor is bound to MMP-9, calculated as 1/k_off) of 300 min^[1].
A favorable IC50value of 143 μM afforded a therapeutic index (IC₅₀/K_i for MMP-9) ratio of 7530, indicating that (R)-ND-336 is not cytotoxic^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

(R)-ND-336 (50 μg/wound/day for 14 days) accelerates wound healing faster^[1].
(R)-ND-336 has an AUC of 1.3 μM•min after topical administration and 35 μM•min following intravenous dosing, for an AUC_top/AUC_iv ratio of 3.7%, indicating minimal absorption after topical administration in db/db mice^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

371.90

C₁₆H₁₈ClNO₃S₂

2252493-33-5

NCC1=CC=C(OC2=CC=C(C=C2)S(C[C@@H]3SC3)(=O)=O)C=C1.Cl

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Trung T Nguyen, et al. Validation of Matrix Metalloproteinase-9 (MMP-9) as a Novel Target for Treatment of Diabetic Foot Ulcers in Humans and Discovery of a Potent and Selective Small-Molecule MMP-9 Inhibitor That Accelerates Healing. J Med Chem. 2018 Oct  [Content Brief]